Lv32
386 积分 2022-03-15 加入
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
6天前
已完结
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers
13天前
已完结
The regulation of IgA class switching
25天前
已完结
Insights into the B cell specific process of immunoglobulin class switch recombination
25天前
已完结
Class-switch recombination: interplay of transcription, DNA deamination and DNA repair
25天前
已完结
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma
27天前
已完结
Immunogenicity of CAR T cells in cancer therapy
27天前
已完结
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
27天前
已完结
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy
28天前
已完结
CAR T cell persistence in cancer
28天前
已完结
皖公网安备34019202002308
